title: Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study.
abstract: OBJECTIVE
  To assess the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome.
  
  
  METHODS
  This study evaluated 64 eyes of 32 patients (age: 62.6±12.8 years (mean±SD)) in whom treatment with 0.1% sodium hyaluronate was insufficiently responsive. The eyes were randomly assigned to one of the two regimens in each patient: topical administration of sodium hyaluronate and diquafosol tetrasodium in one eye, and that of sodium hyaluronate in the other. Before treatment, and 2 and 4 weeks after treatment, we determined tear volume, tear film break-up time (BUT), fluorescein and rose bengal vital staining scores, subjective symptoms, and adverse events.
  
  
  RESULTS
  We found a significant improvement in BUT (P=0.049, Dunnett test), fluorescein and rose bengal staining scores (P=0.02), and in subjective symptoms (P=0.004 for dry eye sensation, P=0.02 for pain, and P=0.02 for foreign body sensation) 4 weeks after treatment in the diquafosol eyes. On the other hand, we found no significant change in these parameters after treatment in the control eyes.
  
  
  CONCLUSIONS
  In dry eyes, where sodium hyaluronate monotherapy was insufficient, diquafosol tetrasodium was effective in improving objective and subjective symptoms, suggesting its viability as an option for the additive treatment of such eyes.
authors.affiliation: Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa 252-0374, Japan. kamiyak-tky@umin.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Kamiya
authors.forename: M
authors.initials: M
authors.lastname: Nakanishi
authors.forename: R
authors.initials: R
authors.lastname: Ishii
authors.forename: H
authors.initials: H
authors.lastname: Kobashi
authors.forename: A
authors.initials: A
authors.lastname: Igarashi
authors.forename: N
authors.initials: N
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004359:Drug Therapy, Combination; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D019793:Fluorescein / Q000378:metabolism; D005456:Fluorescent Dyes / Q000378:metabolism; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011122:Polyphosphates / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D058912:Purinergic P2Y Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D012395:Rose Bengal / Q000378:metabolism; D013666:Tears / Q000737:chemistry; D014500:Uracil Nucleotides / Q000008:administration & dosage* / Q000009:adverse effects; D055675:Viscosupplements / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D005456:Fluorescent Dyes; D009883:Ophthalmic Solutions; D011122:Polyphosphates; D058912:Purinergic P2Y Receptor Agonists; D014500:Uracil Nucleotides; D055675:Viscosupplements; D012395:Rose Bengal; C403315:diquafosol; D006820:Hyaluronic Acid; D019793:Fluorescein